Novartis
NVS
$97.78
Share price
0.35%
Change (1 day)
-4.67%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Novartis (NVS) - Total debt
Total debt on the balance sheet as of March 2024 : $27.28 B
According to Novartis's latest financial reports the company's total debt is $27.28 B. A company’s total debt is the sum of all current and non-current debts.
Novartis - Total debt on balance sheet (from 2001 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $26.34 B | -5.59% |
| 2022-12-31 | $27.90 B | -10.04% |
| 2021-12-31 | $31.02 B | -18.04% |
| 2020-12-31 | $37.85 B | 29.87% |
| 2019-12-31 | $29.14 B | -9.17% |
| 2018-12-31 | $32.09 B | 12.89% |
| 2017-12-31 | $28.42 B | 20.01% |
| 2016-12-31 | $23.68 B | 8.15% |
| 2015-12-31 | $21.90 B | 7.57% |
| 2014-12-31 | $20.35 B | 13.64% |
| 2013-12-31 | $17.91 B | -9.18% |
| 2012-12-31 | $19.72 B | -2.49% |
| 2011-12-31 | $20.22 B | -11.83% |
| 2010-12-31 | $22.94 B | 64.96% |
| 2009-12-31 | $13.90 B | 97.7% |
| 2008-12-31 | $7.03 B | 25.78% |
| 2007-12-31 | $5.59 B | -22.49% |
| 2006-12-31 | $7.21 B | -12.1% |
| 2005-12-31 | $8.20 B | 25.18% |
| 2004-12-31 | $6.55 B | 19.87% |
| 2003-12-31 | $5.47 B | 4.43% |
| 2002-12-31 | $5.23 B | 14.74% |
| 2001-12-31 | $4.56 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $29.33 B | 7.51% | 🇺🇸 USA |
 Pfizer PFE | $70.84 B | 159.66% | 🇺🇸 USA |
 Abbott Laboratories ABT | $15.62 B | -42.72% | 🇺🇸 USA |
 Sanofi SNY | $20.36 B | -25.35% | 🇫🇷 France |
 Merck MRK | $35.05 B | 28.48% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 110.41% | 🇺🇸 USA |
 AstraZeneca AZN | $34.55 B | 26.63% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $22.93 B | -15.93% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $20.15 B | -26.14% | 🇮🇱 Israel |